HO156, AMLSG 28-18: A phase 3, multicenter, open-label, randomized study with gilteritinib or midostaurine in combination with induction and consolidation chemotherapy followed by 1 year of maintenance treatment in patients with newly diagnosed acute myeloid leukaemia (AML) or myelodysplastic syndromes with excess blasts (MDS-EB2) with FLT3 mutations who are eligible for intensive chemotherapy